11.07.11
Horizon Discovery Ltd. has entered a strategic partnership agreement with Promega Corp. for the delivery of endogenous gene reporting capabilities with Promega’s luciferase and HaloTag reporter technologies, using Horizon’s homologous recombination-based precision genome editing technology (rAAV GENESIS).
The partnership aims to develop next-generation predictive human disease models as they occur in patient tumors. To date, Horizon has applied its rAAV gene-editing platform to reconstitute more than 370 cancer mutations and variations in human cell lines that serve as patient-relevant, predictive in vitro models of genetic disease.
Additional objectives will be to enable the study of tumor response to anti-cancer treatments in real-time, by offering in vivo xenografts of Horizon’s tumorigenic engineered isogenic cell lines with incorporated Promega reporter tags. Preliminary studies have shown clear images of tumor graft response to targeted molecular therapies.
Dr. Paul Morrill, commercial director, Horizon Discovery, said, “I am pleased to announce this long-term collaboration that will enable further elucidation of genetic drivers of disease, and subsequent development of a new toolbox of targeted therapies. For the first time, investigators will be able to directly trace the relationship between protein expression, the interaction of that target protein within its molecular pathway, and how it is encoded by the genome.”
The partnership aims to develop next-generation predictive human disease models as they occur in patient tumors. To date, Horizon has applied its rAAV gene-editing platform to reconstitute more than 370 cancer mutations and variations in human cell lines that serve as patient-relevant, predictive in vitro models of genetic disease.
Additional objectives will be to enable the study of tumor response to anti-cancer treatments in real-time, by offering in vivo xenografts of Horizon’s tumorigenic engineered isogenic cell lines with incorporated Promega reporter tags. Preliminary studies have shown clear images of tumor graft response to targeted molecular therapies.
Dr. Paul Morrill, commercial director, Horizon Discovery, said, “I am pleased to announce this long-term collaboration that will enable further elucidation of genetic drivers of disease, and subsequent development of a new toolbox of targeted therapies. For the first time, investigators will be able to directly trace the relationship between protein expression, the interaction of that target protein within its molecular pathway, and how it is encoded by the genome.”